HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)
Clinical trials for HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA) explained in plain language.
Never miss a new study
Get alerted when new HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA) trials appear
Sign up with your email to follow new studies for HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental cell therapy targets tough blood cancers and anemia
Disease control Recruiting nowThis early-phase study is testing a new cell therapy called GT801 in 28 adults with relapsed or hard-to-treat B-cell blood cancers (like leukemia and lymphoma) or autoimmune hemolytic anemia (AIHA). The therapy uses a patient's own immune cells, modified to attack CD19-positive c…
Matched conditions: HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Experimental cell therapy takes aim at stubborn blood cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental immune cell therapy called GT719 in 34 adults with relapsed or refractory CD19-positive B-cell blood cancers (certain leukemias and lymphomas). The treatment uses specially engineered cells to target and destroy cancer cells. The …
Matched conditions: HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)
Phase: EARLY_PHASE1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cell therapy GT719 targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing an experimental cell therapy called GT719 in 46 adults with relapsed or treatment-resistant B-cell lymphoma or leukemia that tests positive for CD19. The study aims to see if the treatment is safe and how well it works. Participants receive a sin…
Matched conditions: HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA)
Phase: PHASE1, PHASE2 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 26, 2026 18:26 UTC